Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935956 · ClinicalTrials.gov registry record
Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy
A clinical trial of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by NeuraLace Medical.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT05935956: Completed study of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by NeuraLace Medical.
NCT05935956 is a study of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy that has completed, run by NeuraLace Medical. The registered enrollment target is 14 participants, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05935956, a study of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy, has completed, sponsored by NeuraLace Medical.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy
Primary Outcome
The primary effectiveness endpoint is to demonstrate a reduction in pain at Day 90 as compared to Baseline where pain is measured in-clinic using a visual analog scale (VAS). Scores on the VAS range from 0 (no pain) to 10 (worst possible pain).
Conditions Studied
Interventions
- DEVICE Magnetic Peripheral Nerve Stimulation
Study Locations (1)
North Carolina
- Carolinas Pain Institute and Center for Clinical Research - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2023-12-21 |
What the finished NCT05935956 record still lists
NCT05935956 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Peripheral Nerve Stimulation is the first listed.
NCT05935956 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05935956 about?
NCT05935956 is a clinical study titled "Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy". Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy
What is the current status of trial NCT05935956?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2023-06-09. Estimated completion is 2023-12-21.
What conditions does trial NCT05935956 study?
This clinical trial studies the following conditions: Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy, Neuralgia.
What interventions are being tested in trial NCT05935956?
The interventions under investigation include: Magnetic Peripheral Nerve Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05935956?
This trial is sponsored by NeuraLace Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05935956 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05935956's enrollment target sits among peer trials
14 32nd of 35 higher than 4 of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Virtual Reality (VR) Self-Hypnosis Software
RECRUITING · NA
-
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
RECRUITING · NA
-
The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
RECRUITING · Phase 4
-
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
RECRUITING · Phase 1
-
Brain Connectivity Changes With Spinal Cord Stimulation and Treatment of Chronic Pain: A Resting State NIRS/EEG Study
RECRUITING
-
Diabetic Neuropathy in Spinal Cord Stimulator Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy